Navigation Links
Vasogen Announces 2008 Year-End Results
Date:2/27/2009

MISSISSAUGA, ON, Feb. 27 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today reported the results of operations for the fiscal year ended November 30, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At November 30, 2008, our cash and cash equivalents totaled $8.6 million, compared with $23.5 million at November 30, 2007 and $9.8 million at August 31, 2008. As of January 31, 2009, our cash balance was $8.5 million.

The net loss for the fourth quarter of 2008 was $0.8 million, or $0.03 per common share. We incurred a net loss for the year ended November 30, 2008 of $16.1 million, or $0.72 per common share, compared with a net loss of $28.8 million, or $1.46 per common share for the same period in 2007. A key driver of this decrease was lower compensation costs, reduced stock compensation expense, lower infrastructure and other support costs driven by lower employee numbers in 2008, and a decrease in the foreign exchange loss that was incurred in the prior period. In addition, the decrease was impacted by a reduction in expenses resulting from the repayment of the senior convertible notes in April 2007.

    Corporate Update

    -   During 2008, we implemented our restructuring plan to significantly
        reduce the rate at which we use our cash and to focus our efforts on
        opportunities that the Board and Management believe are most likely
        to provide shareholder value. As a result, we discontinued
        maintaining the necessary quality processes and personnel to support
        European commercialization and any clinical development of our
        Celacade technology, materially reduced expenses associated with the
        VP series of drugs, and reduced the number of full-time employees
        from 104 to six. We also retained JMP Securities 
'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Sale of Patent Application and Provides Corporate Update
2. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
3. Vasogen Provides Corporate Update
4. Vasogen Announces Third Quarter 2008 Results
5. Vasogen Announces Second Quarter 2008 Results
6. Vasogen Provides Corporate Update
7. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
9. Vasogen Announces Implementation of Strategic Restructuring Plan
10. Vasogen Announces First Quarter 2008 Results
11. Vasogen to Webcast its Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Sapphire Energy, Inc. ... announced the appointment of biotechnology veteran James Levine ... of directors. Levine replaces Cynthia ,CJ, Warner, who is ... remain chairman of the company,s board of directors. ... mission to deliver commercial scale algae-based fuels has been ...
(Date:7/28/2014)... According to a new market research report published ... Joint) Market (By Technology - Stem Cell Therapy, ... Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products ... Growth, Trends and Forecast, 2013 - 2019" the ... valued at USD 2.6 billion in 2012 and ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ -   JOLT ... group of companies to join its growing portfolio of ... of Toronto,s JOLT accelerator, and ... on the roster. Since its launch ... have successfully raised  $7.5M of financing. Now at 23 ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Immunomic Therapeutics, ... researchers to further develop potential treatments for glioblastoma multiforme ... in combination with their patented vaccine platform, LAMP-vax. ... University, are based on the work of John H. ... at The Preston Robert Tisch Brain Tumor Center at ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4
... David Letterman, here are the top 10 reasons to be at ... can pick up some great toys for the kids. Attention-grabbing ... floor, where representatives of 61 nations and 48 states have set ... the giveaways. , , Crowd at BIO ...
... The state Assembly on Thursday passed AB 499, a proposed ... ,The bill would outlaw the cloning of embryos both for ... therapeutic cloning, the making of a cloned embryo for the ... if it were to become law would go up to ...
... - Educators and video-game developers gathered last week ... traditional classroom and textbook education models, which speakers agreed ... annual Games+Learning+Society conference was sponsored by ... of the Advanced Academic Distributed Learning (ADL) Co-Lab ...
Cached Biology Technology:From the BIO floor 2From the BIO floor 3Gaming technologies alter classroom, textbook models 2Gaming technologies alter classroom, textbook models 3Gaming technologies alter classroom, textbook models 4Gaming technologies alter classroom, textbook models 5
(Date:7/28/2014)... for Biologically Inspired Engineering at Harvard University today ... commercialized by a newly formed private company to ... medicine products. The announcement follows a ... Development (OTD) and the start-up Emulate Inc., relating ... Organs-on-Chips platform. , "This is a big ...
(Date:7/27/2014)... might have survived the asteroid strike that wiped them ... later in history, scientists say. , A fresh study ... helped palaeontologists to build a new narrative of the ... They found that in the few million years before ... was experiencing environmental upheaval. This included extensive volcanic activity, ...
(Date:7/27/2014)... potential for global climate change to cut food supplies. ... the interactions between increasing temperature and air pollution ... , A new study involving researchers at MIT shows ... policymakers need to take both warming and air pollution ... looked in detail at global production of four leading ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... Calif. June 23, 2010. The city recreation programs of ... on natural resources themes such as wildlife, forestry, aquatics ... participants will explore their local environment, and learn about ... supported by a special program sponsored by the USDA ...
... A new animal model of atherosclerosis has allowed researchers to ... the initial stages of the process, before a plaque appears ... June 15 in Blood, the journal of the ... to definitively show that disturbances in the patterns of blood ...
... 2010) -- The p53 tumor suppressor gene, the "guardian ... mutated in many cancers. It encodes one of a family ... death. Mutations in p53 allow cells to escape normal growth ... book from Cold Spring Harbor Laboratory Press, The p53 ...
Cached Biology News:Summer day camps provide fun; environmental education activities for Humboldt County youth 2To predict atherosclerosis, follow the disturbed blood flow 2
MOUSE ANTI NEUROFILAMENTS 140+160 KD...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MOUSE ANTI HUMAN COMPLEMENT SC5B-9...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
Biology Products: